Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. XENE
stocks logo

XENE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.203
+43.23%
--
--
-1.130
+36.14%
--
--
-1.186
+10.81%
Estimates Revision
The market is revising Upward the revenue expectations for Xenon Pharmaceuticals Inc. (XENE) for FY2025, with the revenue forecasts being adjusted by 0.37% over the past three months. During the same period, the stock price has changed by 13.77%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.37%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.19%
In Past 3 Month
Stock Price
Go Up
up Image
+13.77%
In Past 3 Month
Wall Street analysts forecast XENE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XENE is 55.59 USD with a low forecast of 44.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast XENE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XENE is 55.59 USD with a low forecast of 44.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 44.610
sliders
Low
44.00
Averages
55.59
High
65.00
Current: 44.610
sliders
Low
44.00
Averages
55.59
High
65.00
JPMorgan
NULL -> Overweight
maintain
$57 -> $60
2025-11-18
Reason
JPMorgan
Price Target
$57 -> $60
2025-11-18
maintain
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Xenon Pharmaceuticals to $60 from $57 and keeps an Overweight rating on the shares. The firm updated the company's model.
RBC Capital
Outperform
maintain
$55 -> $58
2025-11-04
Reason
RBC Capital
Price Target
$55 -> $58
2025-11-04
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Xenon Pharmaceuticals to $58 from $55 and keeps an Outperform rating on the shares. The timelines for X-TOLE2 remain intact for early 2026, and the firm continues to see a high chance of success at 75% based on prior azetukalner phase 2b and OLE data, the analyst tells investors in a research note.
Wells Fargo
Benjamin Burnett
Overweight
downgrade
$48 -> $44
2025-11-04
Reason
Wells Fargo
Benjamin Burnett
Price Target
$48 -> $44
2025-11-04
downgrade
Overweight
Reason
Wells Fargo analyst Benjamin Burnett lowered the firm's price target on Xenon Pharmaceuticals to $44 from $48 and keeps an Overweight rating on the shares. The firm thinks the X-TOLE2 study is likely to work as it's designed after a highly positive Phase 2 study. That said, Wells thinks "bogey" for median seizure reduction is being debated, and call commentary about this could drive some weakness in shares.
Wells Fargo
Overweight
initiated
$48
2025-09-02
Reason
Wells Fargo
Price Target
$48
2025-09-02
initiated
Overweight
Reason
Wells Fargo assumed coverage of Xenon Pharmaceuticals with an Overweight rating and $48 price target. The company expects the readout of its Phase 3 X-TOLE2 study involving lead asset, azetukalner, in Focal Onset Seizures in early 2026, and the firm believes that azetukalner is likely to succeed in X-TOLE2 given the strong Phase 2 data, the analyst tells investors in a research note. The 10mg dose worked in Phase 2, implying some room for efficacy pullback in Phase 3, the firm added.
RBC Capital
Brian Abrahams
Outperform
downgrade
$57 -> $55
2025-08-12
Reason
RBC Capital
Brian Abrahams
Price Target
$57 -> $55
2025-08-12
downgrade
Outperform
Reason
RBC Capital analyst Brian Abrahams lowered the firm's price target on Xenon Pharmaceuticals to $55 from $57 but keeps an Outperform rating on the shares after its Q2 results. The enrollment completion for X-TOLE2 pivotal along with intact timeline for early-FY26 top-line readout is likely to reassure investors, the analyst tells investors in a research note. RBC adds that it continues to have high confidence based on prior azetukalner phase 2 and OLE data, as well as historical phase 2 to phase 3 translatability in FOS, that the Kv7 will recapitulate its compelling efficacy and safety profile and unlock a $1.2B long-term opportunity.
Wells Fargo
Mohit Bansal
Overweight
maintain
$50 -> $47
2025-05-13
Reason
Wells Fargo
Mohit Bansal
Price Target
$50 -> $47
2025-05-13
maintain
Overweight
Reason
Wells Fargo analyst Mohit Bansal lowered the firm's price target on Xenon Pharmaceuticals to $47 from $50 and keeps an Overweight rating on the shares. After enrollment completion was pushed back from the second half of 2024 and now top-line data pushed to early 2026, the firm can see investor concerns around X-TOLE2 program and lack of catalyst this year. Though not statistical significant, Mt. Sinai data was reassuring for MDD activity, Wells adds.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Xenon Pharmaceuticals Inc (XENE.O) is -9.44, compared to its 5-year average forward P/E of -12.05. For a more detailed relative valuation and DCF analysis to assess Xenon Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.05
Current PE
-9.44
Overvalued PE
-9.48
Undervalued PE
-14.61

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-7.13
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-3.23
Undervalued EV/EBITDA
-11.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2107.77
Current PS
0.00
Overvalued PS
5744.96
Undervalued PS
-1529.42
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

XENE News & Events

Events Timeline

(ET)
2025-11-03
16:07:38
Xenon Pharmaceuticals announces Q3 EPS of $1.15, slightly below consensus of $1.16
select
2025-10-16 (ET)
2025-10-16
08:42:44
Xenon Pharmaceuticals names Tucker Kelly as CFO
select
2025-08-11 (ET)
2025-08-11
16:10:52
Xenon Pharmaceuticals reports Q2 EPS $1.07 vs. (75c) last year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
07:21 AMGlobenewswire
Xenon Pharmaceuticals Grants 39,250 Stock Options to New Employees
  • Employee Incentive Program: On December 4, 2025, Xenon Pharmaceuticals granted 39,250 stock options to five new non-officer employees, aimed at attracting and retaining talent, thereby enhancing the company's competitiveness in the biopharmaceutical sector.
  • Option Details: The options have an exercise price of $44.61 per share, equal to the closing price on the grant date, vesting over four years with 25% vesting after the first year and the remainder vesting monthly, ensuring long-term employee commitment.
  • Strategic Implications: By implementing this incentive program, Xenon not only boosts employee loyalty but also attracts top talent in the rapidly evolving neuroscience field, facilitating future innovation and growth.
  • Clinical Development Progress: Xenon's lead molecule, azetukalner, is currently in Phase 3 clinical trials for treating epilepsy and major depressive disorder, and the option grants will help attract key personnel to accelerate the R&D process.
[object Object]
Preview
5.0
07:13 AMNewsfilter
Xenon Pharmaceuticals Grants 39,250 Stock Options to New Employees
  • Employee Incentive Program: Xenon Pharmaceuticals grants 39,250 stock options to five new non-officer employees, aimed at attracting talent and enhancing employee loyalty, in accordance with Nasdaq Listing Rule 5635(c)(4), which is expected to improve overall team stability.
  • Option Details: The options have an exercise price of $44.61 per share, equal to the closing price on the grant date, and will vest over four years with 25% vesting on the first anniversary and the remainder vesting monthly, ensuring long-term employee commitment to the company.
  • Strategic Implications: By implementing this incentive measure, Xenon not only attracts key talent but also strengthens its market position in the highly competitive biopharmaceutical industry, driving innovation in the neuroscience sector.
  • R&D Progress: Xenon is advancing its lead molecule azetukalner in Phase 3 clinical trials for epilepsy and major depressive disorder, and the stock option grants will help attract more specialized talent to accelerate the R&D process.
[object Object]
Preview
4.0
11-18Benzinga
JP Morgan Keeps Overweight Rating on Xenon Pharmaceuticals and Increases Price Target to $60

  • Real-time Intelligence: Benzinga Pro offers fast and accurate stock market intelligence to help traders make informed decisions.

  • Exclusive Stories: The platform provides exclusive news stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing insights and strategies.

  • Trade Alerts: Users can receive the fastest news alerts to ensure they never miss a trading opportunity.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Xenon Pharmaceuticals Inc (XENE) stock price today?

The current price of XENE is 44.61 USD — it has increased 0.72 % in the last trading day.

arrow icon

What is Xenon Pharmaceuticals Inc (XENE)'s business?

Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.

arrow icon

What is the price predicton of XENE Stock?

Wall Street analysts forecast XENE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XENE is 55.59 USD with a low forecast of 44.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Xenon Pharmaceuticals Inc (XENE)'s revenue for the last quarter?

Xenon Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Xenon Pharmaceuticals Inc (XENE)'s earnings per share (EPS) for the last quarter?

Xenon Pharmaceuticals Inc. EPS for the last quarter amounts to -1.15 USD, increased 41.98 % YoY.

arrow icon

What changes have occurred in the market's expectations for Xenon Pharmaceuticals Inc (XENE)'s fundamentals?

The market is revising Upward the revenue expectations for Xenon Pharmaceuticals Inc. (XENE) for FY2025, with the revenue forecasts being adjusted by 0.37% over the past three months. During the same period, the stock price has changed by 13.77%.
arrow icon

How many employees does Xenon Pharmaceuticals Inc (XENE). have?

Xenon Pharmaceuticals Inc (XENE) has 316 emplpoyees as of December 05 2025.

arrow icon

What is Xenon Pharmaceuticals Inc (XENE) market cap?

Today XENE has the market capitalization of 3.45B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free